A61K 40/4215
Receptors for tumor necrosis factors [tnf]
Official title: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
A61K40/4215 (Receptors for tumor necrosis factors [tnf]) appears on 346 US grants and 870 published applications in this corpus.
Search patents in A61K- Granted patents
- 346
- Published applications
- 870
- Assignees
- 300
- Inventors
- 1,514
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 5 |
| 2004 | 2 | 4 |
| 2005 | 0 | 1 |
| 2006 | 0 | 3 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 3 |
| 2011 | 0 | 4 |
| 2012 | 1 | 1 |
| 2013 | 1 | 2 |
| 2014 | 0 | 0 |
| 2015 | 1 | 3 |
| 2016 | 2 | 7 |
| 2017 | 4 | 16 |
| 2018 | 5 | 23 |
| 2019 | 16 | 62 |
| 2020 | 37 | 89 |
| 2021 | 42 | 105 |
| 2022 | 48 | 119 |
| 2023 | 41 | 120 |
| 2024 | 45 | 111 |
| 2025 | 56 | 114 |
| 2026 | 42 | 77 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Compositions and methods for modifying a target nucleic acid6 Oct 2026US 12,753,412 B2The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
- Compositions and methods for selective protein degradation29 Sep 2026US 12,747,272 B2Novartis AG
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Methods of manufacturing t cell therapies17 Sep 2026US 2026/0272978 A1Celgene Corporation
- Chimeric antigen receptor targeting bcma and use thereof10 Sep 2026US 2026/0265371 A1National Cancer Center
- Anti-cd27 monoclonal antibody and use thereof10 Sep 2026US 2026/0265393 A1Shanghai Celgen Bio-Pharmaceutical Co., Ltd.
- Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy3 Sep 2026US 2026/0258358 A1Board of Regents, The University of Texas System
- Compositions and methods for cellular immunotherapy27 Aug 2026US 2026/0250405 A1Fred Hutchinson Cancer Center
Most cited
By later US patents
- Chimeric antigen receptors targeting B-cell maturation antigen85US 9,765,342 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2017
- Activated dendritic cells and methods for their activation54US 6,017,527 AImmunex Corporation · 2000
- Method of stimulating an immune response with activated dendritic cells52US 6,497,876 B1Immunex Corporation · 2002
- Methods of making T cell compositions28US 10,479,975 B2bluebird bio, Inc. · 2019
- Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins26US 9,017,679 B2University of Miami · 2015